Abstract
Prostate cancer (PC) is the second most common cause of cancer-related mortality in US men, and 180,890 of new PC cases occurred in 2016 [1]. At the time of diagnosis, approximately 12% of patients had locally advanced PC, and about 4% of patients had PC with metastasis [2]. Cure for localized PC that is newly diagnosed is available with definitive therapy. However, almost 30% of patients with PC experience recurrence of PC and castration-resistant PC (CRPC) [2]. Many new drugs have been approved by the US Food and Drug Administration (FDA) as a therapeutic option for CRPC. Various pathways and targets have demonstrated major advances in understanding the mechanisms of acquiring castration resistance and showing progression of PC. In this chapter, the clinical trials in CRPC will be elaborated. A large number of new agents for CRPC that is based on various mechanisms are currently being studied worldwide. Clinical trials of CRPC are summarized in Table 24.1.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
